Table 5.
Long-term analyses: outcomes
| Treatment sequence | Time horizon (years) | Sarilumab outcomes | Adalimumab outcomes | Incremental QALYs: sarilumab vs adalimumab | ||||
|---|---|---|---|---|---|---|---|---|
| Time on treatment 1 | LYs | QALYs | Time on treatment 1 | LYs | QALYs | |||
| Next line: csDMARD palliative treatment | 1 | 0.77 | 0.96 | 0.38 | 0.72 | 0.96 | 0.37 | 0.02 |
| 5 | 1.93 | 4.38 | 1.69 | 1.66 | 4.38 | 1.60 | 0.09 | |
| 10 | 2.66 | 7.79 | 2.75 | 2.26 | 7.77 | 2.61 | 0.14 | |
| Next lines: tofacitinib > csDMARD palliative treatment | 5 | 1.93 | 4.39 | 1.82 | 1.66 | 4.38 | 1.75 | 0.08 |
| 10 | 2.66 | 7.81 | 3.01 | 2.26 | 7.80 | 2.89 | 0.12 | |
| Next lines: etanercept > csDMARD palliative treatment | 5 | 1.93 | 4.39 | 1.95 | 1.66 | 4.39 | 1.89 | 0.06 |
| 10 | 2.66 | 7.84 | 3.25 | 2.26 | 7.83 | 3.15 | 0.11 | |
| Next lines: etanercept > tofacitinib > csDMARD palliative treatment | 5 | 1.93 | 4.40 | 2.02 | 1.66 | 4.40 | 1.97 | 0.06 |
| 10 | 2.66 | 7.86 | 3.44 | 2.26 | 7.85 | 3.34 | 0.10 | |
Abbreviation: csDMARD, conventional synthetic disease-modifying antirheumatic drug.